Last reviewed 2026-04-20 · How we verify

aflibercept 8 mg

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nasopharyngitis
• Hypertension
• Cataract
• Urinary tract infection
• COVID-19
• Conjunctival haemorrhage - Study eye
• Back pain
• Conjunctival haemorrhage
• Visual acuity reduced - Study eye
• Fall
• Neovascular age-related macular degeneration - Fellow eye
• Cough

Key clinical trials

• A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration (PHASE3)
• Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) (PHASE3)
• High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes (PHASE4)
• A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema
• The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
• A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) (PHASE2, PHASE3)
• Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration
• Home Monitoring in eAMD Treatment

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• aflibercept 8 mg CI brief — competitive landscape report
• aflibercept 8 mg updates RSS · CI watch RSS
• Yeungnam University College of Medicine portfolio CI